The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis

Figure 3

Subgroup and sensitivity analyses stratified by treatment, disease, and trial characteristics. HR: hazard ratio; IOCT: immuno-oncology combination treatment, CI: confidence interval.